## ICMJE DISCLOSURE FORM

Date:_7/22/2023
/our Name:lvy Riano
Manuscript Title: The Beginning of the Perioperative Immunotherapy Era in Early-Stage Non-Small Cell Lung Cancer: A
Need to Make Careful Decision Together
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	pranning of the work
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events	V. Nana		
6	Payment for expert testimony	_XNone		
	testimony			
7	Support for attending	XNone		
	meetings and/or travel			
	Detects along a discussion	V. Nava		
8	Patents planned, issued or pending	XNone		
9	Participation on a Data	_XNone		
	Safety Monitoring Board or			
10	Advisory Board  Leadership or fiduciary role	V. Nana		
10	in other board, society,	_XNone		
	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	X None		
	·			
12	Receipt of equipment,	_XNone		
	materials, drugs, medical			
	writing, gifts or other			
12	services Other financial or non-	V None		
13	financial interests	XNone		
	illialiciai liiterests			
Plea	se summarize the above co	nflict of interest in the fol	lowing box:	
l l	y Riano M.D. does not have an	y conflict of interests.		
	•	,		

Please place an "X" next to the following statement to indicate your agreement:

\_X\_\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

## ICMJE DISCLOSURE FORM

Date:	7/21/2023	
Your Name:	Konstantin Dr	agnev
Manuscript Title	e: The Beginning of the	Perioperative Immunotherapy Era in Early-Stage Non-Small Cell Lung Cancer: A
Need to Make C	areful Decision Togeth	er
Manuscript nun	nber (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
		Time frame: Since the initial	planning of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone			
Time frame: past 36 months					
2	Grants or contracts from any entity (if not indicated in item #1 above).	Merck, Roche/Genentech, Eli Lilly, Novartis	Clinical trial funding to the institution		
3	Royalties or licenses	XNone			

4	Consulting fees	XNone				
5	Payment or honoraria for	_XNone				
	lectures, presentations,					
	speakers bureaus,					
	manuscript writing or					
_	educational events	X None				
6	Payment for expert testimony	XNone				
7	Support for attending	X None				
,	meetings and/or travel					
	l					
8	Patents planned, issued or	X None				
	pending					
9	Participation on a Data	X None				
	Safety Monitoring Board or					
	Advisory Board					
10	Leadership or fiduciary role	XNone				
	in other board, society,					
	committee or advocacy					
	group, paid or unpaid					
11	Stock or stock options	_XNone				
42	Descript of a pulicas and	V Name				
12	Receipt of equipment,	XNone				
	materials, drugs, medical writing, gifts or other					
	services					
13	Other financial or non-	X None				
	financial interests					
	rse summarize the above co		-			
Plea	Please place an "X" next to the following statement to indicate your agreement:					

\_X\_\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

## ICMJE DISCLOSURE FORM

Date:7/19/2023
Your Name:Joseph D. Phillips
Manuscript Title: The Beginning of the Perioperative Immunotherapy Era in Early-Stage Non-Small Cell Lung Cancer: A
Need to Make Careful Decision Together
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	None	
	medical writing, article processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	Research Grant	KSQ Therapeutics, Inc
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
	•		
7	Support for attending	None	
•	meetings and/or travel		
	ee aa, e. e.ave.		
		N.	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	Board Member	Thoracic Surgery Outcomes Research Network (unpaid)
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		
Dloo	sa summariza tha abaya sa	nflict of interest in the	following how

## Please summarize the above conflict of interest in the following box

Joseph D. Phillips receives a research Grant from KSQ Therapeutics Inc that is not related to this work. He also unpaid member of the Board of Directors of the non-profit Thoracic Surgery Outcomes Research Network.				

Please place an "X" next to the following statement to indicate your agreement:

\_\_x\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.